IVIG a Winner for Dermatomyositis

(MedPage Today) -- Treatment with intravenous immunoglobulins (IVIG) for dermatomyositis was effective in a pivotal phase III randomized trial, a researcher reported.
At week 16, 78.72% of patients receiving IVIG were considered responders versus...